Tel: 1-631-504-6093

BTK inhibitor Velexbru approved new indications: treatment of two kinds of malignant lymphoma, the total remission rate is 90%

Ono Pharmaceutical¬†recently announced that its BTK inhibitor Velexbru¬†(tirabrutinib hydrochloride,¬†80mg tablet) has been approved in Japan for the treatment of Fahrenheit macroglobulinemia (WM) and lymphocytic lymphoma (LPL). Velexbru is a highly […]

Read More →